Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Common Equity: 2009-2024

Historic Common Equity for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $6.4 billion.

  • UNITED THERAPEUTICS's Common Equity rose 8.02% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 8.02%. This contributed to the annual value of $6.4 billion for FY2024, which is 7.67% up from last year.
  • As of FY2024, UNITED THERAPEUTICS's Common Equity stood at $6.4 billion, which was up 7.67% from $6.0 billion recorded in FY2023.
  • UNITED THERAPEUTICS's Common Equity's 5-year high stood at $6.4 billion during FY2024, with a 5-year trough of $3.4 billion in FY2020.
  • For the 3-year period, UNITED THERAPEUTICS's Common Equity averaged around $5.7 billion, with its median value being $6.0 billion (2023).
  • Data for UNITED THERAPEUTICS's Common Equity shows a peak YoY rose of 24.77% (in 2023) over the last 5 years.
  • Over the past 5 years, UNITED THERAPEUTICS's Common Equity (Yearly) stood at $3.4 billion in 2020, then climbed by 16.60% to $4.0 billion in 2021, then climbed by 21.16% to $4.8 billion in 2022, then climbed by 24.77% to $6.0 billion in 2023, then climbed by 7.67% to $6.4 billion in 2024.